Systemic Antibiotics

shevyatiwari's version from 2015-08-16 10:39


Question Answer
Is the pro drugF, the metabolite of lincomycin
If erythromycin resistant and clindamycin sensitive, a D zone test may be usefulT - will inform if there is inducible resistance
Dose adjustment is required for renal and hepatic failureF - it is required for liver failure, not renal
Rates of C diff are very lowF, 0.1-10%

Section 2

Question Answer
Tigecycline is similar to macrolidesF, to tetracyclines
Analogue of TCNF, analogue of minocycline
BacteriostaticT, like minocycline
Can cause tooth discolouraton, pancreatitis, hypertriglyceridaemia, T
Cat DT
Interacts with warfarinT - reduces cleraance

Section 3

Question Answer
Linezolid is an oxazolidoneT
Binds to 23S unit of 50S ribosomal unitT
Cross resistant with penicillinF, no cross resistance with any antimicrobial
Widespread activity in multi drug resistanceT
Poor bioavailbilityF, 100%
Metabolism unaffected by CYP3A4T
Serotonin syndrome, optic, peripheral neuropathy, myelosuppression are possibleT
Cat CT
Interacts with MAO's, SSRI's, sympathomimetic, dopaminergic agentsT

Section 4

Question Answer
Quinupristin and dalfopristin are semisynthetic antibiotics given IVT
Bind to 30S ribosomal subunit causing irreversible inhibition of bacterial protein synthesisF, 50S
No effect on CYP3A4F, potent inhibitor
Can cause increased bilirubin by 2 timesF, by 5 times

Section 5

Question Answer
Daptomycin is a lipopeptide available for topcial useF, for IV use
Broad spectrum of activityF, bactericidal to gram positive
Neuropathy and paraesthesias are documetned S/ET
Myopathy is seen at low dosesF, high doses
Weekly CK is required for monitoringT

Section 6

Question Answer
Lipoglycopeptides include telavancin, dalbavancin, oritavancinT
First generation semi synthetic lipoglycopeptidesF, second generation
Related to clindamycinF, related to vancomycin
Treat multi resistant GN organismsF, GP organisms
Dalbavancin and oritavancin are administered less frequently than telavancin so are more usefulT
Significant drug interactions already identifiedF, none to date